Summary

The global market for Influenza Vaccine was estimated to be worth US$ 9135 million in 2024 and is forecast to a readjusted size of US$ 13500 million by 2031 with a CAGR of 5.5% during the forecast period 2025-2031.
Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
Market Driver:The Influenza Vaccine market is driven by the rising global awareness of flu prevention and increasing government initiatives to promote vaccination programs. Seasonal influenza poses a significant public health burden, leading to hospitalizations and fatalities, particularly among high-risk populations such as the elderly, young children, and immunocompromised individuals. Governments and health organizations, including the WHO and CDC, actively support annual flu vaccination campaigns to reduce disease transmission. Additionally, advancements in vaccine technology, such as cell-based and recombinant influenza vaccines, are improving vaccine efficacy and production efficiency, further driving market growth.
Market Challenge:Despite its importance, the Influenza Vaccine market faces challenges related to vaccine hesitancy, manufacturing constraints, and viral mutations. Public skepticism regarding vaccine safety and effectiveness, fueled by misinformation, hampers vaccination rates in some regions. Additionally, influenza viruses undergo frequent genetic mutations, requiring annual vaccine updates and posing challenges in predicting dominant strains. Manufacturing influenza vaccines is also time-sensitive, as traditional egg-based production methods have limitations in scalability and response speed during pandemics. These factors can impact supply chain stability and overall vaccine accessibility.
Global key players of Pandemic Influenza Vaccine include Sanofi, CSL and GSK, etc. The top five players hold a share about 80%. North America is the largest market, has a share about 50%.
This report aims to provide a comprehensive presentation of the global market for Influenza Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Influenza Vaccine by region & country, by Type, and by Application.
The Influenza Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza Vaccine.
Market Segmentation
By Company
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics
Segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Segment by Application
6 Months to 3 Years
> 3 Years
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Influenza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Influenza Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Influenza Vaccine Product Introduction
1.2 Global Influenza Vaccine Market Size Forecast
1.2.1 Global Influenza Vaccine Sales Value (2020-2031)
1.2.2 Global Influenza Vaccine Sales Volume (2020-2031)
1.2.3 Global Influenza Vaccine Sales Price (2020-2031)
1.3 Influenza Vaccine Market Trends & Drivers
1.3.1 Influenza Vaccine Industry Trends
1.3.2 Influenza Vaccine Market Drivers & Opportunity
1.3.3 Influenza Vaccine Market Challenges
1.3.4 Influenza Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Influenza Vaccine Players Revenue Ranking (2024)
2.2 Global Influenza Vaccine Revenue by Company (2020-2025)
2.3 Global Influenza Vaccine Players Sales Volume Ranking (2024)
2.4 Global Influenza Vaccine Sales Volume by Company Players (2020-2025)
2.5 Global Influenza Vaccine Average Price by Company (2020-2025)
2.6 Key Manufacturers Influenza Vaccine Manufacturing Base and Headquarters
2.7 Key Manufacturers Influenza Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Influenza Vaccine
2.9 Influenza Vaccine Market Competitive Analysis
2.9.1 Influenza Vaccine Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Influenza Vaccine Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Vaccine as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Trivalent Influenza Vaccine
3.1.2 Quadrivalent Influenza Vaccine
3.2 Global Influenza Vaccine Sales Value by Type
3.2.1 Global Influenza Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Influenza Vaccine Sales Value, by Type (2020-2031)
3.2.3 Global Influenza Vaccine Sales Value, by Type (%) (2020-2031)
3.3 Global Influenza Vaccine Sales Volume by Type
3.3.1 Global Influenza Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Influenza Vaccine Sales Volume, by Type (2020-2031)
3.3.3 Global Influenza Vaccine Sales Volume, by Type (%) (2020-2031)
3.4 Global Influenza Vaccine Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 6 Months to 3 Years
4.1.2 > 3 Years
4.2 Global Influenza Vaccine Sales Value by Application
4.2.1 Global Influenza Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Influenza Vaccine Sales Value, by Application (2020-2031)
4.2.3 Global Influenza Vaccine Sales Value, by Application (%) (2020-2031)
4.3 Global Influenza Vaccine Sales Volume by Application
4.3.1 Global Influenza Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Influenza Vaccine Sales Volume, by Application (2020-2031)
4.3.3 Global Influenza Vaccine Sales Volume, by Application (%) (2020-2031)
4.4 Global Influenza Vaccine Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Influenza Vaccine Sales Value by Region
5.1.1 Global Influenza Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Influenza Vaccine Sales Value by Region (2020-2025)
5.1.3 Global Influenza Vaccine Sales Value by Region (2026-2031)
5.1.4 Global Influenza Vaccine Sales Value by Region (%), (2020-2031)
5.2 Global Influenza Vaccine Sales Volume by Region
5.2.1 Global Influenza Vaccine Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Influenza Vaccine Sales Volume by Region (2020-2025)
5.2.3 Global Influenza Vaccine Sales Volume by Region (2026-2031)
5.2.4 Global Influenza Vaccine Sales Volume by Region (%), (2020-2031)
5.3 Global Influenza Vaccine Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Influenza Vaccine Sales Value, 2020-2031
5.4.2 North America Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Influenza Vaccine Sales Value, 2020-2031
5.5.2 Europe Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Influenza Vaccine Sales Value, 2020-2031
5.6.2 Asia Pacific Influenza Vaccine Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Influenza Vaccine Sales Value, 2020-2031
5.7.2 South America Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Influenza Vaccine Sales Value, 2020-2031
5.8.2 Middle East & Africa Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Influenza Vaccine Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Influenza Vaccine Sales Value and Sales Volume
6.2.1 Key Countries/Regions Influenza Vaccine Sales Value, 2020-2031
6.2.2 Key Countries/Regions Influenza Vaccine Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Influenza Vaccine Sales Value, 2020-2031
6.3.2 United States Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Influenza Vaccine Sales Value, 2020-2031
6.4.2 Europe Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Influenza Vaccine Sales Value, 2020-2031
6.5.2 China Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.5.3 China Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Influenza Vaccine Sales Value, 2020-2031
6.6.2 Japan Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Influenza Vaccine Sales Value, 2020-2031
6.7.2 South Korea Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Influenza Vaccine Sales Value, 2020-2031
6.8.2 Southeast Asia Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Influenza Vaccine Sales Value, 2020-2031
6.9.2 India Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.9.3 India Influenza Vaccine Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Sanofi
7.1.1 Sanofi Company Information
7.1.2 Sanofi Introduction and Business Overview
7.1.3 Sanofi Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Sanofi Influenza Vaccine Product Offerings
7.1.5 Sanofi Recent Development
7.2 CSL
7.2.1 CSL Company Information
7.2.2 CSL Introduction and Business Overview
7.2.3 CSL Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 CSL Influenza Vaccine Product Offerings
7.2.5 CSL Recent Development
7.3 GSK
7.3.1 GSK Company Information
7.3.2 GSK Introduction and Business Overview
7.3.3 GSK Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 GSK Influenza Vaccine Product Offerings
7.3.5 GSK Recent Development
7.4 Viatris
7.4.1 Viatris Company Information
7.4.2 Viatris Introduction and Business Overview
7.4.3 Viatris Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Viatris Influenza Vaccine Product Offerings
7.4.5 Viatris Recent Development
7.5 AstraZeneca
7.5.1 AstraZeneca Company Information
7.5.2 AstraZeneca Introduction and Business Overview
7.5.3 AstraZeneca Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 AstraZeneca Influenza Vaccine Product Offerings
7.5.5 AstraZeneca Recent Development
7.6 Hualan Bio
7.6.1 Hualan Bio Company Information
7.6.2 Hualan Bio Introduction and Business Overview
7.6.3 Hualan Bio Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Hualan Bio Influenza Vaccine Product Offerings
7.6.5 Hualan Bio Recent Development
7.7 Changchun Institute of Biological
7.7.1 Changchun Institute of Biological Company Information
7.7.2 Changchun Institute of Biological Introduction and Business Overview
7.7.3 Changchun Institute of Biological Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Changchun Institute of Biological Influenza Vaccine Product Offerings
7.7.5 Changchun Institute of Biological Recent Development
7.8 Sinovac
7.8.1 Sinovac Company Information
7.8.2 Sinovac Introduction and Business Overview
7.8.3 Sinovac Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Sinovac Influenza Vaccine Product Offerings
7.8.5 Sinovac Recent Development
7.9 BCHT
7.9.1 BCHT Company Information
7.9.2 BCHT Introduction and Business Overview
7.9.3 BCHT Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 BCHT Influenza Vaccine Product Offerings
7.9.5 BCHT Recent Development
7.10 Jiangsu GDK
7.10.1 Jiangsu GDK Company Information
7.10.2 Jiangsu GDK Introduction and Business Overview
7.10.3 Jiangsu GDK Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Jiangsu GDK Influenza Vaccine Product Offerings
7.10.5 Jiangsu GDK Recent Development
7.11 KM Biologics
7.11.1 KM Biologics Company Information
7.11.2 KM Biologics Introduction and Business Overview
7.11.3 KM Biologics Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 KM Biologics Influenza Vaccine Product Offerings
7.11.5 KM Biologics Recent Development
8 Industry Chain Analysis
8.1 Influenza Vaccine Industrial Chain
8.2 Influenza Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Influenza Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Influenza Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer